Plasmapheresis in Thrombotic Thrombocytopenic Purpura

McLeod, Bruce C.

doi:10.1001/archinte.1980.00330190071022

Cited by 28 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of combined therapeutic plasmapheresis and renal replacement therapy is occasionally necessary for the treatment of patients with immune-mediated renal disease [1], sepsis [2], fulminant hepatic failure [3,4], and thrombotic thrombocytopenic purpura (TTP) /hemolytic uremic syndrome (HUS) [5][6][7][8][9][10]. Providing centrifugation plasmapheresis to patients receiving renal replacement therapy is usually uncomplicated, as most are treated with either hemodialysis or peritoneal dialysis.…”

Section: Introductionmentioning

confidence: 99%

Concurrent centrifugation plasmapheresis and continuous venovenous hemodiafiltration

Yorgin¹,

Eklund

Al-Uzri³

et al. 2000

Pediatric Nephrology

View full text Add to dashboard Cite

Continuous venovenous hemofiltration/hemodiafiltration (CVVH/D) is commonly used to provide renal replacement therapy for critically ill patients who are hemodynamically unstable. Occasionally, the addition of plasmapheresis therapy is necessary for some conditions, including immune-mediated acute renal failure, sepsis, fulminant hepatic failure, and thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Most tertiary care facilities provide centrifugation plasmapheresis instead of membrane plasmapheresis, because of the requirement for both therapeutic plasma exchange and pheresis of cellular blood products. We report a new technique where centrifugation plasmapheresis and CVVHD (P-CVVHD) are combined and used concurrently. Blood from the patient was concurrently filtered utilizing a Hospal BSM 22 machine with a Multiflow 60 hemofilter and a Cobe Spectra continuous cell separator in a parallel configuration. P-CVVHD is technically possible and can be used for long periods of time with limited risks. There may be advantages to P-CVVHD compared with discontinuous combined CVVH/D and plasmapheresis therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Concurrent centrifugation plasmapheresis and continuous venovenous hemodiafiltration

Yorgin¹,

Eklund

Al-Uzri³

et al. 2000

Pediatric Nephrology

View full text Add to dashboard Cite

show abstract

“…(In what follows, 'TPE' will imply this FFP replacement strategy.) This experience was readily confirmed in other centers [17][18][19]. The mechanism of action of TPE was unknown; however, the apparent necessity for FFP replacement, plus reports of a few patients who responded to FFP infusion alone, suggested that deficiency of a plasma factor might be involved [20].…”

Section: Treatment With Therapeutic Plasma Exchangementioning

confidence: 75%

Evidence based therapeutic apheresis in autoimmune and other hemolytic anemias

McLeod

2007

Current Opinion in Hematology

View full text Add to dashboard Cite

The proper role of therapeutic plasma exchange in the treatment of autoimmune hemolytic anemia remains uncertain. Therapeutic plasma exchange continues to be indicated for idiopathic thrombotic thrombocytopenic purpura regardless of ADAMTS13 levels, but more accessible and physiological ADAMTS13 assays may raise questions about the rationale for and value of plasma exchange in ADAMTS13 nondeficient patients. Oral iron chelation may obviate the need for red cell exchange as a means to prevent iron overload in chronically transfused patients with sickle cell disease.

show abstract

“…There is no effective therapy for TTP, but plasma therapy (plasma exchange, plasmapheresis or infusion), alone or combined with other forms of therapy, can dramatically improve the prognosis of patients with TTP. The mechanism by which the therapy works is not well understood [4]. The decision to implement plasma therapy (infusion in patients with an inherited disease, exchange in acquired disease) does not warrant the availability of ADAMTS13 values in real time [3].…”

Section: Discussionmentioning

confidence: 99%

Thrombotic Thrombocytopenic Purpura Associated with Myelodysplastic Syndrome

Malik¹,

Mokraoui²,

Razaq³

et al. 2020

Cureus

View full text Add to dashboard Cite

Myelodysplasia and thrombotic thrombocytopenic purpura (TTP) are both rare diseases. TTP is a blood abnormality in which blood clots form in blood vessels leading to fatal outcomes. Myelodysplastic syndrome is a group of disorders caused by poorly formed blood cells or ones that do not work properly. We are hereby presenting the case of a 69-year-old female who presented with anemia, thrombocytopenia, changes in mental status and reduced kidney function, and further investigations revealed that the patient had underlying myelodysplasia.

show abstract

Plasmapheresis in Thrombotic Thrombocytopenic Purpura

Cited by 28 publications

References 11 publications

Concurrent centrifugation plasmapheresis and continuous venovenous hemodiafiltration

Concurrent centrifugation plasmapheresis and continuous venovenous hemodiafiltration

Evidence based therapeutic apheresis in autoimmune and other hemolytic anemias

Thrombotic Thrombocytopenic Purpura Associated with Myelodysplastic Syndrome

Contact Info

Product

Resources

About